<DOC>
	<DOCNO>NCT00150982</DOCNO>
	<brief_summary>To determine mechanism action alefacept patient psoriasis .</brief_summary>
	<brief_title>Alefacept Mechanism Action Psoriasis</brief_title>
	<detailed_description>The purpose study well understand mechanism action FDA approve drug ( alefacept ) . Subjects enrolled give alefacept 7.5 mg intravenously weekly basis 12 week . Response assess improvement PASI score . The responder get treatment nonresponders receive additional 4 week therapy . Skin biopsy obtain throughout study T-cell apoptosis correlate clinical response . There placebo group . The duration study approximately 1 year .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Inclusion Criteria Alefacept indicate treatment adult patient ( 18 year old ) moderate severe chronic plaque psoriasis candidate systemic therapy phototherapy . Patients must least one plaque least 2.5 cm diameter ( biopsy ) . Exclusion Criteria CD4 &lt; 400/ml WBC less low level normal report laboratory &lt; 5 % Body Surface Area involve psoriasis Serious infection e.g. , latent active tuberculosis History AIDS Hepatitis B , C , internal cancer , lymphoma , untreated cutaneous basal squamous cell carcinoma Systemic antipsoriasis medication phototherapy within 28 day first dose Alefacept Topical antipsoriasis medication within 14 day first dose Alefacept , except moisturizers , tar shampoo ( exception , Elidel permit applied face , groin axillae area . These area biopsied . ) Inability understand consent form comply study requirement Pregnancy lactation Concurrent medical illness would make participation clinical trial illadvised Any contraindication use alefacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
</DOC>